NovaBridge Biosciences NBP
1.38
(0.07)
(4.83%)
as of 25 Sep
- Market cap
- $172.8M
- P/E
- 0.0×
Follow NBP
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Sep '25 | Jun '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.36 | 14.19 | 22.54 | 21.75 | |
Current Ratio |
7.64 | 14.47 | 22.82 | 22.35 | |
Net Debt/EBITDA |
0.00 | 0.00 | 23.28 | 32.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 1.42 | 0.00 | |
Capex/Depreciation |
(1.64) | 0.00 | 0.09 | — | |
Interest Coverage |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (0.10) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.10) | 0.00 | |
Cash per Share |
0.00 | 0.00 | 2.03 | 2.14 | |
Shareholders Equity per Share |
0.00 | 0.00 | 2.41 | 2.52 | |
Interest Debt per Share |
— | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 2.41 | 2.52 | |
Free Cash Flow |
(33.92) | 1.84 | (7.80) | — | |
Working Capital |
172.08 | 216.68 | 160.29 | 165.48 | |
Capital Expenditures |
(0.99) | 0.00 | 0.04 | — | |
Net Current Asset Value |
167.57 | 214.28 | 157.67 | 162.63 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Net Profit Margin |
— | — | 0.00% | 0.00% | |
| Other line items | |||||
Average Assets |
222.11 | 255.05 | 230.27 | 104.47 | |
Average Common Equity |
201.13 | 238.40 | 216.68 | 220.17 |
Columns are period end dates